Galvus Safety Trial Reconsidered In Light Of Novartis Cost Concerns

Novartis' NDA for its oral type 2 diabetes drug Galvus (vildagliptin) will remain in a holding pattern in the U.S. until the firm has a clearer idea of whether it can gain FDA approval without excessive expenditures to gather additional safety data

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet